Efficacy of Single-Agent Anti–PD-1 or Combined With Ipilimumab for Mucosal Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study
Ann. Oncol 2022 Jun 16;[EPub Ahead of Print], F Dimitriou, K Namikawa, ILM Reijers, EI Buchbinder, JA Soon, A Zaremba, P Teterycz, MJ Mooradian, E Armstrong, Y Nakamura, MG Vitale, LE Tran, X Bai, C Allayous, S Provent-Roy, A Indini, P Bhave, M Farid, KC Kähler, I Mehmi, V Atkinson, O Klein, CJ Stonesifer, F Zaman, A Haydon, RD Carvajal, O Hamid, R Dummer, A Hauschild, MS Carlino, M Mandala, C Robert, C Lebbe, J Guo, DB Johnson, PA Ascierto, AN Shoushtari, RJ Sullivan, B Cybulska-Stopa, P Rutkowski, L Zimmer, S Sandhu, CU Blank, SN Lo, AM Menzies, GV LongFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.